Johnson & Johnson

NYSE:JNJ  
171.79
+1.81 (+1.06%)
5:12:07 PM EDT: $171.72 -0.07 (-0.04%)
Products, Regulatory

Janssen Says New Phase 3 Study Results Show Imbruvica(Ibrutinib)-Based Combination Regimen As All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival In Adult Patients

Published: 06/12/2021 11:16 GMT
Johnson & Johnson (JNJ) - Janssen Says New Phase 3 Study Results Show Imbruvica® (ibrutinib)-based Combination Regimen As an All-oral Fixed-duration Treatment Demonstrated Superior Progression-free Survival in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Janssen - Glow Study Presented As a Late-breaking Abstract at European Hematology Association (eha) Virtual Congress.